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Background: The aim of this study was to determine whether the incidence and survival of patients with
end-stage kidney disease (ESKD) due to polycystic kidney disease (PKD) has changed in Australia and New
Zealand.
Methods: Data for all PKD patients who developed ESKD and commenced renal replacement therapy (RRT)
was assessed using the Australia and New Zealand Dialysis and Transplant Registry from 1963 to 2014.
Results: A total 4678 patients with ESKD due to PKD received RRT during the study period. The incidence
rate of ESKD (per million population per year) due to PKD rose by 3.2-fold (1970–2010), but the percentage
increase between each decade decreased (54.4, 43.8, 25.6 and 6.57%). The median age of onset of new
patients developing ESKD has been stable since 1990. Haemodialysis was the most common initial mode
of RRT (between 62 and 76% of patients) whereas 24–29% received peritoneal dialysis. The 5-year survival
rate of PKD patients on RRT (censored for transplantation and adjusted for age) improved from 26 to 84%,
with the percentage increase between each successive time period being 123, 7, 21, 19 and 7.4%. The
percentage of deaths on RRT due to cerebrovascular disease declined from 15 to 6%.
Conclusions: The incidence and age of onset of ESKD due to PKD has remained unchanged in the modern
era though patient survival on RRT has continued to improve. These data suggest that the development
and implementation of disease-specific treatments prior to RRT is needed to effectively diminish the
incidence of ESKD due to PKD.
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Autosomal dominant polycystic kidney disease (ADPKD) is
the most common monogenetic disorder causing end-stage
kidney disease (ESKD) in adults [1–5]. It is a slowly progres-
sive adult-onset chronic kidney disease that is characterized
by the formation and growth of numerous fluid-filled cysts
in the kidneys, which cause renal enlargement and pain,
hypertension, intracranial aneurysms and cardiovascular dis-
ease [4]. ADPKD is caused by heterozygous germ-line* Correspondence: g.rangan@sydney.edu.au
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PKD2 (15% of cases) [6]. These genes encode the proteins
polycystin-1 and polycystin-2, which maintain the normal
geometric structure of the distal nephron in the kidney [7].
Patients with PKD2 and hypomorphic PKD1mutations have
a better renal prognosis and a delayed onset of ESKD, com-
pared to patients with truncating PKD1mutations [7].
Previous observational studies, predominantly of dialysis
registry data, have shown that the age of onset of ESKD
due to ADPKD has increased over time and that patient
survival on renal replacement therapy (RRT) has also im-
proved [3, 8–11]. Orskov et al. reported that the survival of
Danish patients with ESKD treated with RRT has steadily
increased over an 18-year period from 1990 to 2007 [11].
Similarly, a single-center study from the Oxford Renal Unitle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Incidence of end-stage kidney disease to PKD from
1970 to 2010 (incidence rates expressed per million population
per year, 95% confidence interval [CI])
Year Incident Rate of ESKD due to PKD





1970–1974 2.04 1.71 2.42
1975–1979 2.50 2.18 2.85
1980–1984 3.15* 2.80 3.54
1985–1989 3.92* 3.54 4.33
1990–1994 4.53* 4.13 4.95
1995–1999 5.62* 5.18 6.08
2000–2004 5.69* 5.26 6.14
2005–2009 7.63* 7.15 8.12
2010–2014 6.57* 6.15 7.02
*P < 0.001 compared to 1970
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period (1971–2000). Lastly, dialysis registry data from
Europe (1991–2010) showed that the incidence rate of
ESKD due to ADPKD has increased slightly over the last
two decades (1991–2009) [12].
Over the last 50 years, there have been major improve-
ments in the management of hypertension, hyperlipidemia
and the treatment of anemia due to ESKD [13]. In
Australia, angiotensin-converting enzyme inhibitors were
first introduced onto the national Pharmaceutical Benefits
Scheme (a government subsidized program for prescription
drugs) in 1983, whereas erythropoietin stimulating agents
and angiotensin receptor blockers became available in 1992
and 1997 respectively. Lowering blood pressure and treat-
ment with cholesterol-lowering agents reduces the rate of
renal cyst growth in ADPKD and could potentially delay
the age of onset of ESKD [2, 14, 15]. Moreover, the treat-
ment of anemia associated with ESKD improves outcomes
in patients receiving RRT [16]. The Australia and New
Zealand Dialysis and Transplant Registry (ANZDATA) has
been recording the incidence, prevalence and outcome of
all maintenance dialysis and transplant patients in Australia
and New Zealand since 1963 [17]. This registry therefore
provides an extensive timeframe to determine whether im-
provements in medical therapy might precede changes in
the incidence of ESKD due to PKD and patient survival on
RRT. Thus, the aim of the study was to determine whether
there have been time-specific changes in the incidence of




The ANZDATA registry records the incidence, prevalence
and outcome of all maintenance dialysis and transplant
patients in Australia and New Zealand. Data are collected
by means of survey forms for each patient at 6-month
intervals until 2004, after which it was altered to a yearly
survey ending on December 31, together with notification
of key events in real time The cohort study included all
patients with ESKD with or without PKD enrolled in the
ANZDATA commencing RRT in Australia and New
Zealand between May 15, 1963 and December 31, 2014.
Patients who commenced RRT overseas were excluded.
All patients entered into the ANZDATA were considered
by the treating nephrologist to have ESKD due to PKD and
therefore thought to require long-term RRT at the time they
were enrolled in the registry. The assignment of the primary
renal disease as “polycystic kidney disease” is made by the
treating nephrologist on clinical grounds. This definition has
been unchanged over the course of the study. There is no
requirement for confirmatory genetic testing. Treatment
modality (dialysis vs. pre-emptive transplant) was assigned
at the commencement of RRT. The primary outcomesexamined were the incidence rate and age of onset of ESKD
as well as the survival rate and characteristics of RRT. The
treatment era was determined by the date of commencing
dialysis, and divided into 10-year periods: 1963–1974, 1975–
1984, 1985–1994, 1995–1994, 2005–2014.
Statistical analysis
Analyses were performed on a de-identified extract from
the ANZDATA Registry. Confidence intervals for inci-
dence rates were calculated using a Poisson distribution,
which were also used to compare rates between groups.
Patient survival and renal allograft survival was esti-
mated by Kaplan–Meier analysis; age-adjusted curves
were adjusted to median age at dialysis start. Patients
were not censored in the survival analysis when the dia-
lysis modality was switched from peritoneal dialysis to
hemodialysis or vice versa. Differences between Kaplan-
Meier curves were tested using the log-rank test. Com-
peting risk analyses of cumulative incidence were used
for the incidence of transplantation (with death as a
competing risk). The non-PKD group is shown as
“Total” or sub-divided into “Vascular/Diabetes” and
“Non-vascular” causes. Data were analysed using Stata/
IC 14.1 (Stata Corporation, College Station, TX, USA).
P-values <0.05 were considered statistically significant.
Results
Incidence rate and median age of onset of renal
replacement therapy in PKD
A total 4678 patients with ESKD due to PKD received
RRT or underwent pre-emptive renal transplantation in
Australia and New Zealand between 1963 and 2014,
from a population of 70,544 (or 6.6% of total). Of the
4678 patients, 23 were of Aboriginal/Torres Strait Is-
lander heritage (total population of 4534) and 98 were of
Maori/Islander descent (total population of 6661).
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as per million population) increased by 3.2-fold between
1970 and 2010 (Table 1). However, the percentage in-
crease in the incidence rates between each successive
decade decreased between 1970 and 2010 (22.5; 56.8,
43.3 and 35.8%).
The median age of onset of ESKD due to PKD in-
creased over time but has been relatively stable since
1990 (Fig. 1a and b). Prior to 1990, the median age of
onset of ESKD in PKD patients was higher than in pa-
tients without PKD (i.e., the non-PKD group), whereas
in the most recent time-period (1990–2014) this has
been reversed (Fig. 1b).
The changes in the incidence of RRT and absolute
numbers of patients, according to age category, areA
C
E
Fig. 1 Changes in the age of onset of end-stage kidney disease due to PKD. a
age of onset according to the time period; for both PKD and non-PKD groups t
ESKD due to PKD according to age group; d Incidence of ESKD due to non-PKD
to age group, receiving RRT over the study period; f Percentage of PKD patientsshown in Fig. 1c–f. Overall, the incidence of ESKD in
PKD patients younger than 25 years of age has been a
relatively small proportion of the total RRT population,
and has been stable over time (Fig. 1c). In the other cat-
egories, the incidence of ESKD due to PKD in patients
aged between 25 and 44 years and ≥65, increased over
time but has been relatively stable since 1990 (Fig. 1c, e
and f ). In contrast in the non-PKD population, the num-
ber of new patients ≥65 years of age who commenced
RRT has rapidly increased since 1990 (Fig. 1c and d).
The changes in the absolute numbers and the age-
specific proportions are shown in Fig. 1e and f. Patients
aged between 45 and 64 years of age were the most
common category in all time periods, representing
between approximately half to three-quarters of theB
D
F
Median age of onset over the duration of the study (1963–2014); b Median
he age of incidence varies significantly over time (P< 0.001); c Incidence of
according to age group; e Absolute numbers of PKD patients, according
according to age, over the study period
Fig. 2 Changes in the relative proportions initial RRT modality in non-PKD and PKD patients according to the time-period. For each of the groups, the modality
of treatment varies significantly over time (p< 0.0001). Abbreviations: Tx, pre-emptive kidney transplantation; PD, peritoneal dialysis; HD, hemodialysis
Table 2 Kidney transplant graft survival in transplanted patients with PKD and other primary kidney diseases (mean percentage and
95% confidence interval [CI])
PKD 0.5 years 1 year 3 years 5 years
1963–1974 58.5 [49.3–0.66.7] 53.7 [44.5–0.62.0] 44.7 [35.8–53.2] 37.4 [28.9–45.9]
1975–1984 56.9 [51.5–61.9] 53.5 [48.1–58.5] 47.1 [41.7–52.2] 40.1 [34.9–45.2]
1985–1994 84.3 [80.9–87.2] 83.2 [79.7–86.1] 78.0 [74.1–81.3] 74.5 [70.5–78.0]
1995–2004 93.0 [90.8–94.7] 91.8 [89.5–93.7] 88.6 [86.0–90.8] 84.2 [81.2–86.8]
2005–2014 97.6 [96.5–98.3] 97.1 [96.0–97.9] 93.9 [92.2–95.2] 90.4 [88.2–92.2]
Non-PKD
Total
1963–1974 63.1 [60.7–65.3] 58.1 [55.7–60.5] 48.5 [46.1–0.50.8] 42.1 [39.7–44.4]
1975–1984 63.5 [62.0–65.0] 58.7 [57.1–60.2] 48.4 [46.8–50.0] 42.3 [40.7–43.9]
1985–1994 84.9 [83.9–85.9] 82.7 [81.6–83.7] 74.8 [73.6–76.0] 67.3 [65.9–68.6]
1995–2004 92.7 [92.0–93.3] 91.3 [90.5–92.0] 85.9 [84.9–86.7] 79.7 [78.6–80.7]
2005–2014 95.8 [95.4–96.3] 94.4 [93.9–95.0] 89.1 [88.3–89.8] 83.3 [82.3–84.3]
Diabetic/Vascular
1963–1974 52.4 [43.3–60.8] 46.8 [37.8–55.2] 36.9 [28.5–45.4] 34.5 [26.2–42.9]
1975–1984 51.9 [46.7–56.8] 46.3 [41.2–51.2] 34.7 [29.9–39.5] 27.8 [23.3–32.3]
1985–1994 83.4 [80.1–86.3] 80.0 [76.5–83.1] 70.8 [66.8–74.3] 61.3 [57.2–65.2]
1995–2004 91.2 [89.1–92.9] 89.5 [87.3–91.4] 82.0 [79.3–84.4] 75.7 [72.6–78.4]
2005–2014 94.7 [93.5–95.7] 93.0 [91.6–94.1] 86.1 [84.1–87.9] 80.1 [77.5–82.3]
Non-vascular
1963–1974 63.9 [61.5–66.2] 59.0 [56.6–61.4] 49.4 [46.9–51.8] 42.7 [40.3–45.2]
1975–1984 64.8 [63.2–66.4] 60.0 [58.4–61.6] 49.9 [48.3–51.6] 43.9 [42.2–45.6]
1985–1994 85.1 [84.0–86.1] 83.0 [81.8–84.1] 75.4 [74.1–76.6] 68.1 [66.6–69.4]
1995–2004 93.0 [92.2–93.6] 91.6 [90.7–92.3] 86.5 [85.5–87.5] 80.4 [79.3–81.5]
2005–2014 96.1 [95.6–96.6] 94.9 [94.3–95.4] 89.8 [89.0–90.6] 84.1 [83.0–85.2]
Note: Non-PKD group shown as “Total” or sub-divided into “Vascular/Diabetes” and “Non-vascular”
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Fig. 3 a Cumulative incidence of time to first transplant over the five study periods in PKD patients; b Cumulative incidence of time to first transplant
in non-PKD patients; c Proportion of PKD patients receiving a living donor or deceased donor kidney at the time of transplantion over the study period.
d Proportion of non-PKD patients receiving a living donor or deceased donor kidney at the time of transplantion over the study period
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increase in the proportion of patients older than 65 years
of age (Fig. 1f ).
Characteristics of the initial modality of renal replacement
therapy in PKD
The changes in the initial modality of RRT over time are
shown in Fig. 2. Hemodialysis was the most common
method of initial RRT, with almost three-quarters (62–78%)
of patients being initiated on this modality (Fig. 2). The per-
centage of patients receiving hemodialysis declined slightly
over the last decade due to an increase in pre-emptive
transplantation and this was higher than in the non-PKD
population (Fig. 2). Approximately a quarter of patients
(between 24 and 29%) were initiated on peritoneal dialysis
and this has remained constant throughout the study
periods (Fig. 2).
Renal transplant graft survival in PKD patients was
similar to non-PKD patients (Table 2). The time to the
first renal transplant declined over time, similar to thenon-PKD population (Fig. 3a and b). Live donor kidney
transplantation has increased since 1990 (Fig. 3c).
Survival and death rates on renal replacement therapy
in PKD
The unadjusted 5-year survival of ADPKD patients with
ESKD improved progressively from 52 to 85% over the
study period (Fig. 4a, Table 3). After adjustment for age
the 5-year survival improved from 33 to 89% since 1963
(Fig. 4b, Table 4). When censored for kidney transplant-
ation and adjusted for age, the improvement in 5-year sur-
vival over the study period was more pronounced, and
increased from 26 to 84% (Fig. 4c and d, Tables 5 and 6)
and the percentage change between each successive time
period was 123, 7, 21, 19 and 7.4% respectively. In all
time-periods, survival on RRT in PKD patients was better
than in non-PKD patients (Tables 3, 4, 5 and 6).
There were a total of 2013 deaths during the study
period with an overall death rate of 6.2 deaths per per-
son year. The death rate was lowest in the 25–44 year
A B
C D
Fig. 4 Kaplan-Meier curves showing survival of PKD patients receiving RRT during the study period. Panel a shows unadjusted data, whereas Panel b
shows data adjusted for median age (58 years old). Panel c shows unadjusted data (age) but censored at first transplantation, whereas Panel d shows
adjusted data (age) censored at first transplantation. For all comparisons, the unadjusted and age-adjusted outcomes vary significantly over
time (p< 0.001)
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[<25 years: 4.4 (1.6–11.7); 25–44 years: 2.7 (2.2–3.4);
45–64 years: 4.4 (4.1–4.6); >65 years: 11.9 (11.2–12.6)].
Death due to cerebrovascular accidents were a small
proportion of the overall cause of mortality, and de-
clined from 16% in 1970–1979 to 6% during between
years 2000 and 2011 (Fig. 5). The death rate, as
expressed according to age category, has progressively
declined in PKD group (Fig. 6). However, the improve-
ment in death is less marked in the non-PKD groups
(Fig. 6).
Discussion
The development of end-stage kidney disease is the most
significant clinical complication of PKD. In this study we
investigated the incidence rate, age of onset and survival of
PKD patients receiving RRT in Australia and New Zealand
over a 50-year period to evaluate whether time-dependent
changes have occurred. To our knowledge, this is the lon-
gest longitudinal follow-up of ESKD patients with PKD.
The main findings were that: (i) the median age of onset
and incidence of RRT has increased but relatively stablesince 1990; (ii) the proportion of patients older than 65 years
starting RRT has increased since 1990, representing almost
a quarter of the cohort; (iii) hemodialysis was the
most common initial dialysis RRT modality and tech-
nique survival on peritoneal dialysis was not affected
by PKD; (iv) the percentage of pre-emptive kidney
transplantation as the initial RRT modality has in-
creased; and (v) the 5-year survival of PKD patients
on RRT has continually improved over time.
Previous studies indicate that the population preva-
lence of PKD ranges anywhere from 1 in 400 to 1 in
5000 [1, 18–23]. This wide variation is probably because
the true population prevalence of PKD is virtually im-
possible to determine accurately, as disease penetrance
(diagnosed by renal ultrasound) peaks late in life (after
the age of 60 years), and a high frequency of patients (up
to 50% or more) have a relatively benign life-time course
and do not come to medical detection and/or the de-
velop ESKD [20]. On the other hand, the increasing de-
tection of asymptomatic PKD due to the fact that more
diagnostic tests are being performed for other reasons in
developed nations, may falsely give the impression that
Table 3 Survival rates of incident patients with ESKD (mean percentage and 95% confidence interval [CI])
PKD 0.5 years 1 year 3 years 5 years
1963–1974 90.7 [85.3–94.2] 82.0 [75.4–87.0] 64.0 [56.3–70.6] 52.3 [44.6–59.5]
1975–1984 97.0 [95.1–98.2] 92.9 [90.3–94.8] 76.7 [72.8–80.2] 65.5 [61.2–69.4]
1985–1994 97.0 [95.6–97.9] 94.3 [92.5–95.7] 82.9 [80.2–85.3] 72.1 [69.0–75.0]
1995–2004 98.3 [97.4–98.9] 96.1 [94.9–97.1] 85.8 [83.8–87.6] 77.7 [75.3–79.9]
2005–2014 98.5 [97.8–99.0] 97.1 [96.2–97.8] 91.2 [89.6–92.5] 85.1 [83.1–86.9]
Non-PKD
Total
1963–1974 88.1 [86.7–89.4] 79.6 [77.9–81.3] 61.5 [59.5–63.5] 52.4 [50.3–54.5]
1975–1984 93.3 [92.6–93.9] 86.6 [85.7–87.5] 69.9 [68.7–71.1] 58.9 [57.6–60.1]
1985–1994 94.6 [94.2–95.0] 89.2 [88.6–89.8] 68.7 [67.7–69.5] 54.4 [53.5–55.4]
1995–2004 93.8 [93.5–94.1] 87.6 [87.1–88.1] 66.5 [65.9–67.2] 51.1 [50.4–51.8]
2005–2014 94.0 [93.7–94.3] 89.1 [88.7–89.4] 70.4 [69.8–71.0] 55.2 [55.5–56.0]
Diabetic/Vascular
1963–1974 79.9 [73.4–84.9] 68.8 [61.7–74.9] 43.4 [36.3–50.3] 38.1 [31.2–45.0]
1975–1984 87.0 [84.4–89.1] 76.4 [73.3–79.2] 50.3 [46.8–53.8] 35.6 [32.3–39.0]
1985–1994 92.1 [91.0–93.6] 84.0 [83.6–85.4] 52.6 [50.6–54.4] 33.3 [31.4–35.0]
1995–2004 92.7 [92.2–93.3] 85.1 [84.3–85.8] 58.0 [56.9–59.0] 38.0 [36.9–39.0]
2005–2014 94.0 [93.6–94.3] 88.3 [87.8–88.8] 65.6 [64.7–66.4] 46.6 [45.6–47.6]
Non-vascular
1963–1974 88.9 [87.5–90.2] 80.7 [78.9–82.3] 63.3 [61.1–65.3] 53.8 [51.6–55.9]
1975–1984 94.3 [93.6–94.9] 88.3 [87.3–89.1] 73.1 [71.8–74.3] 62.6 [61.3–64.0]
1985–1994 95.5 [95.0–95.9] 91.0 [90.3–91.6] 74.2 [73.2–75.2] 61.9 [60.8–63.0]
1995–2004 94.6 [94.2–95.0] 89.5 [88.9–90.0] 72.9 [72.0–73.7] 60.8 [59.9–61.7]
2005–2014 94.0 [93.6–94.4] 90.0 [89.4–90.4] 75.8 [74.9–76.6] 65.7 [63.7–65.7]
Note: Non-PKD group shown as “Total” or sub-divided into “Vascular/Diabetes” and “Non-vascular”
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Therefore, dialysis registry data in many ways provides
the most accurate method of capturing changes in the
pattern of disease incidence in the subset of PKD pa-
tients at high risk of renal morbidity.
The results of the current study show that that the in-
cidence of ESKD due to PKD has progressively increased
over the past five decades. Cohort studies from Denmark
and the United States have made the same observation
[9, 11], and these common findings are likely to be a re-
flection of a global increase in the age of patients start-
ing dialysis rather than a feature specific to PKD. For
instance, the median age at starting dialysis patients in
Australia and New Zealand was 59.5 years in 1998
whereas it had increased to 62.9 years for Australia and
to 60.3 years for New Zealand in 2009 [17]. This rising
incidence is therefore common to all types of chronic
kidney disease, including increased access and availabil-
ity of RRT, and increased propensity to offer RRT to
older patients, as well as reductions in the competing
risk of cardiovascular mortality among those with pre-
dialysis chronic kidney disease [24, 25].Recent clinical trials in PKD suggest that a lower blood
pressure and the use of renin-angiotensin inhibitors re-
duces the growth rate of renal cysts in PKD (albeit to a
small extent of ~14% over an 8 year period) but do not
alter the long-term decline in renal function [15]. In the
current study the median age of onset of ESKD in-
creased in PKD patients over time but has been stable
since 1990. Angiotensin-converting enzyme inhibitors
were introduced in Australia in the early 1980s (capto-
pril in 1983 and enalapril in 1986), and first reported to
have renoprotective properties in diabetic kidney disease
in 1992 [26]. However, the real-world utilisation of
renin-angiotensin inhibitors in CKD patients varies be-
tween 58 and 64% [27–29], and hence a longer period of
registry follow-up is required to evaluate their impact on
the incidence of ESKD in ADPKD. Low birth weight has
been also linked to an earlier onset of ESKD but has not
been specifically addressed in the current study [30].
Therefore, the increasing age of onset of ESKD prior to
1990 is more likely due to factors discussed earlier (that
is, improved access to RRT and reductions in cardiovas-
cular death prior to RRT) [13]. Assessment of renal
Table 4 Survival rate (percentage) in incident patients with
ESKD (adjusted for median age, 58 years)
PKD 0.5 years 1 year 3 years 5 years
1963–1974 85.0 71.8 46.9 32.8
1975–1984 96.0 90.4 69.0 54.4
1985–1994 97.0 94.3 82.2 69.7
1995–2004 98.7 97.1 88.6 81.1
2005–2014 99.0 98.1 93.7 88.8
Non-PKD
Total
1963–1974 78.3 64.1 38.1 27.2
1975–1984 89.7 79.7 55.3 39.9
1985–1994 94.3 88.4 64.8 47.2
1995–2004 95.2 90.1 71.1 54.7
2005–2014 95.5 91.8 76.2 61.7
Diabetic/vascular
1963–1974 64.5 47.6 18.2 13.7
1975–1984 83.2 70.2 39.8 24.2
1985–1994 92.0 83.6 51.4 30.8
1995–2004 94.1 87.7 63.3 43.0
2005–2014 95.4 91.0 71.9 54.1
Non-vascular
1963–1974 79.9 65.8 40.3 28.7
1975–1984 91.1 81.7 58.7 43.5
1985–1994 95.1 90.0 70.0 53.7
1995–2004 95.7 91.4 76.1 62.7
2005–2014 95.5 92.3 80.2 69.3
Note: Non-PKD group shown as “Total” or sub-divided into “Vascular/Diabetes”
and “Non-vascular”
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onwards [31] but it is too premature to determine the
impact (if any) this could have on the incidence of
ESKD. In this regard, one caveat to these conclusions is
that the rate of renal disease progression in PKD occurs
slowly over many decades [32]. For example, a recent
analysis suggested that the time taken to transition from
the early stage chronic kidney disease to final phase of
ESKD, is up to seven times slower in PKD than in that
due to other causes (e.g., 17.1 years in PKD vs. 2.5 years
in non-PKD diseases) [33]. Thus, there may be a signifi-
cant lag-time for subtle improvements in pre-dialysis
medical management to be discerned, even with long-
term registry data. Additionally, in this study it is not
possible to model potential factors that may influence
the changes in incidence using registry data because
relevant risk factors (such as the use of ACE inhibitors)
are not part of routine ANZDATA data collection. In-
stead, in the present study we have analyzed temporal
changes in the incidence of the EKSD due to PKD andthen associated them with changes in therapeutics in the
Australia and New Zealand. Future and ongoing pro-
spective studies, such as the CRISP cohort [34], are
more likely to elucidate mechanisms for the underlying
changes in incidence.
Hemodialysis was the most common mode of initial
RRT in PKD patients in Australia and New Zealand, with
only 25% using peritoneal dialysis. This pattern of dialysis
modality utilization remained stable throughout the study
period. It is not clear whether the preference for
hemodialysis was due to patient-dependent and/or health-
care-related biases. Certainly, it has been hypothesized
that PKD patients experience greater technique failure
on peritoneal dialysis due to systemic complications
such as hernias, diverticular disease and reduced peri-
toneal surface area because of nephromegaly [35–37].
However, this hypothesis was not been supported by
others [38]. Lobbedez et al. [39] analyzed 344 French
PKD and did not find evidence of a higher incidence
of technique failure when compared with the non-
PKD group. Similarly, Portoles et al. [40] also found
that a “peritoneal dialysis first” model combined with
an active transplant program has been successful in
Spain. Li et al. [41] also reported peritoneal dialysis is
a feasible treatment option for PKD patients despite a
higher risk of abdominal wall hernia in their analysis
of 126 peritoneal dialysis patients from Hong Kong.
Finally, Courivad et al. also recently verified that the
total kidney volume in PKD patients did not predict
technique survival on peritoneal dialysis [42].
The survival of PKD patients in Australia and New
Zealand improved with each decade, similar to other co-
horts [43]. In our study, the magnitude of increase in
the 1-year survival was most marked between the first
two time periods (1963–1974 to 1975–1984). The pro-
gressive increase in survival could, in part, be explained
by the rise in living kidney transplantation in the study
cohort. The current data are similar to that of Orskov
et al. [11] who followed 693 Danish PKD dialysis pa-
tients for 18 years (1990–2007) and found that there was
a progressive improvement in survival (2-year survival
increased from 80 to 86%, and 5-year survival increased
from 56 to 68%). It is noteworthy that cerebrovascular
disease as a cause of death has decreased in PKD dialysis
patients in our study period. Presumably this is a result
of increased radiological screening for cerebral aneu-
rysms over the study period and improvements in the
management of hypertension [44]. These data are also
consistent with the Danish cohort of PKD dialysis pa-
tients, where it was reported that cerebrovascular
declined by 69% over an 18-year period [45].
There are several limitations of our study. First, it is a
retrospective registry-based analysis and therefore pro-
vides only correlative data associated with the timing of
Table 5 Survival rate in incident patients with ESKD, censored at transplantation (mean percentage and 95% confidence interval [CI])
PKD 0.5 years 1 year 3 years 5 years
1963–1974 96.2 [90.9–98.4] 90.9 [82.7–95.4] 73.7 [59.3–83.7] 51.3 [34.2–66.0]
1975–1984 98.5 [97.0–99.3] 94.8 [92.2–96.6] 80.8 [75.6–85.0] 62.5 [55.3–68.8]
1985–1994 96.9 [95.5–97.9] 94.0 [92.1–95.5] 79.9 [76.4–82.9] 59.9 [55.0–64.3]
1995–2004 98.3 [97.4–98.9] 95.9 [94.5–96.9] 83.1 [80.5–85.3] 69.4 [66.1–72.5]
2005–2014 98.3 [97.6–98.9] 96.6 [95.5–97.4] 87.6 [85.4–89.5] 77.7 [74.4–80.6]
Non-PKD
Total
1963–1974 92.7 [91.4–93.8] 87.1 [85.1–88.8] 66.9 [62.9–70.6] 55.1 [50.1–59.8]
1975–1984 93.8 [93.1–94.4] 87.1 [86.1–88.1] 64.6 [62.9–66.2] 45.9 [43.9–47.9]
1985–1994 94.5 [94.1–95.0] 88.7 [87.9–89.2] 61.9 [60.8–63.0] 40.2 [39.0–41.4]
1995–2004 93.6 [93.3–94.0] 87.0 [86.5–87.5] 62.7 [62.0–63.4] 42.9 [42.1–43.7]
2005–2014 93.7 [93.4–94.0] 88.5 [88.1–88.9] 67.3 [66.6–67.9] 48.5 [47.7–49.3]
Diabetic/Vascular
1963–1974 83.6 [76.8–88.5] 77.7 [69.7–83.8] 55.6 [42.5–66.8] 51.9 [37.8–64.3]
1975–1984 88.7 [86.1–90.8] 78.1 [74.7–81.0] 47.6 [43.1–52.0] 25.3 [21.0–29.8]
1985–1994 92.0 [90.9–93.0] 83.5 [82.0–84.9] 48.4 [46.4–50.5] 24.9 [23.1–26.8]
1995–2004 92.7 [92.1–0.93.2] 84.8 [84.1–85.6] 56.2 [55.1–57.3] 34.1 [33.0–35.2]
2005–2014 93.9 [93.5–94.3] 88.2 [87.6–88.7] 64.2 [63.3–65.0] 43.5 [42.4–44.5]
Non-vascular
1963–1974 93.6 [92.2–94.7] 88.0 [86.0–89.8] 68.0 [63.8–71.9] 55.6 [50.3–60.6]
1975–1984 94.6 [93.9–95.3] 88.6 [87.6–89.69] 67.6 [65.8–69.3] 49.8 [47.6–52.0]
1985–1994 95.5 [95.0–95.9] 90.4 [89.7–91.1] 67.7 [66.4–68.9] 47.3 [45.8–48.8]
1995–2004 94.4 [93.9–94.8] 88.7 [88.1–89.3] 68.3 [67.3–69.3] 51.1 [50.0–52.2]
2005–2014 93.5 [93.1–94.0] 89.0 [88.4–89.6] 71.5 [70.5–72.4] 55.7 [54.4–56.9]
Note: Non-PKD group shown as “Total” or sub-divided into “Vascular/Diabetes” and “Non-vascular”
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of angiotensin converting enzyme inhibitors in Australia.
Second, the categorization of primary renal disease used
by the ANZDATA Registry has remained constant for
many years. We hypothesize the vast majority of patients
in the cohort are likely to have ADPKD because this is
by the most common form of cystic renal disease associ-
ated with CKD and ESKD in adults, with an estimated
population prevalence of ~1:2500 (as discussed earlier in
the discussion) whereas the autosomal recessive variant
falls into the ultra-rare category with an estimated inci-
dence of 1:20,000 to 40,000 [46] and almost all manifest
at birth or early childhood. In this regard, the latter are
more likely to have been reported under the “juvenile
polycystic disease” category, not included in our analysis.
At present, ANZDATA does not collect information re-
garding genetic testing because this is not routine clin-
ical practice in Australia (and most other countries),
where the Pei-Ravine Unified Ultrasound Criteria is the
standard method of diagnosis [47]. The latter has high
sensitivity and specificity (validated against DNA Sanger
Sequencing), and we would anticipate that the majorityof cases identified as PKD in the ANZDATA Registry
would be of the autosomal dominant subtype. Third, as
discussed earlier, it may take a longer period of follow-
up before minor changes in the incidence of ESKD due
to PKD are consistently detected as a result of changes
in pre-dialysis care. Finally, another limitation is the year
in which the entire (100%) Australian and New Zealand
population had full access to dialysis. Although an exact
date cannot be provided, on reviewing the rate of expan-
sion of the entire ESKD population (data not shown), we
noted that the absolute number of patients was more
stable (that is, the rate slowed) from 1970 onwards, and
therefore hypothesise that this period onwards was
period in which the entire population would have had
full access to dialysis treatment options.
Conclusions
In conclusion, the results of this study show that the in-
cidence and age of onset of ESKD in patients with PKD
has increased over a 50-year period in Australia and
New Zealand but have stabilized in the most recent era.
These findings are important because they clearly imply
Table 6 Survival rate (percentage) in incident patients with
ESKD, censored at transplantation and adjusted for median age
(58 years)
PKD 0.5 years 1 year 3 years 5 years
1963–1974 92.6 83.3 56.0 26.4
1975–1984 98.1 93.4 77.5 58.2
1985–1994 96.9 94.1 80.7 62.5
1995–2004 98.5 96.4 85.5 73.8
2005–2014 98.8 97.5 91.0 83.9
Non-PKD
Total
1963–1974 86.1 76.4 47.4 33.7
1975–1984 91.2 82.4 56.1 37.1
1985–1994 94.1 87.7 60.8 39.0
1995–2004 94.4 88.6 66.6 47.5
2005–2014 95.0 90.8 73.0 56.0
Diabetic/vascular
1963–1974 69.1 59.3 29.2 25.2
1975–1984 86.7 74.7 42.4 20.6
1985–1994 91.9 83.3 48.2 24.8
1995–2004 93.6 86.7 60.4 38.5
2005–2014 95.1 90.4 69.9 50.7
Non-vascular
1963–1974 87.8 78.1 49.4 34.8
1975–1984 92.2 83.9 58.9 40.6
1985–1994 94.9 89.5 66.4 45.9
1995–2004 95.0 90.0 71.7 55.3
2005–2014 94.8 91.1 76.7 62.8
Fig. 5 The proportion of deaths due to cerebrovascular accident
over the study period
Fig. 6 Mortality rates (per 100 person-years) during RRT by age and
year of RRT start and category of primary renal disease. The variation
in rates among time periods, age categories and disease categories
are all significant (p < 0.001) and mutually independent
Fernando et al. Population Health Metrics  (2017) 15:7 Page 10 of 12that that the development of disease-specific drugs that
alter renal cyst growth [48] are needed to prevent kidney
failure due to PKD. Because renal cysts in PKD develop
during early childhood, it does not seem unreasonable
to suggest that the implementation of highly effective
and safe disease-specific treatments in a young person
with PKD [49] could potentially eliminate the develop-
ment of ESKD due to this condition in the 21st century.
Further studies will hopefully confirm this hypothesis in
the future.
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